Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Authors
Keywords
-
Journal
HYPERTENSION
Volume 75, Issue 4, Pages 894-901
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-03-12
DOI
10.1161/hypertensionaha.119.11684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study
- (2019) Kazuomi Kario et al. CIRCULATION
- Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
- (2019) Binayak Sinha et al. Diabetes Therapy
- Analysis from the EMPA-REG OUTCOME® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
- (2019) Gert J. Mayer et al. KIDNEY INTERNATIONAL
- Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia
- (2019) Jie Zhang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
- (2019) Chaojie Feng et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
- (2019) Hillel Sternlicht et al. CURRENT HYPERTENSION REPORTS
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors
- (2019) Michael Limenta et al. CLINICAL DRUG INVESTIGATION
- Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescence
- (2019) Sonia Khemais‐Benkhiat et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertension as a Metabolic Disorder and the Novel Role of the Gut
- (2019) Masami Tanaka et al. CURRENT HYPERTENSION REPORTS
- Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
- (2019) Mie K. Eickhoff et al. Journal of Clinical Medicine
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy
- (2018) Ali F. Abdel-Wahab et al. BIOMEDICINE & PHARMACOTHERAPY
- SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
- (2018) M. V. Karg et al. Cardiovascular Diabetology
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- (2018) Annayya R. Aroor et al. Cardiovascular Diabetology
- Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
- (2018) Ningning Wan et al. Frontiers in Endocrinology
- Hematocrit and the incidence of stroke: a prospective, population-based cohort study
- (2018) Renling Yang et al. Therapeutics and Clinical Risk Management
- Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
- (2017) Vance B. Matthews et al. JOURNAL OF HYPERTENSION
- Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats
- (2017) Lei Li et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
- (2016) Asadur Rahman et al. JOURNAL OF HYPERTENSION
- MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2
- (2016) Michael J. Coady et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice
- (2016) Weiling Leng et al. MEDIATORS OF INFLAMMATION
- Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
- (2016) Yumiko Chiba et al. PLoS One
- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
- (2015) William T. Cefalu et al. DIABETOLOGIA
- Hemoglobin mass and intravascular volume kinetics during and after exposure to 3,454-m altitude
- (2015) C. Siebenmann et al. JOURNAL OF APPLIED PHYSIOLOGY
- Renal Oxidative Stress Induced by Long-Term Hyperuricemia Alters Mitochondrial Function and Maintains Systemic Hypertension
- (2015) Magdalena Cristóbal-García et al. Oxidative Medicine and Cellular Longevity
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
- (2014) Ivana Vrhovac et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Regulation of Uric Acid Excretion by the Kidney
- (2012) Michael S. Lipkowitz Current Rheumatology Reports
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Body Fluid Volumes and the Response of Renin and Aldosterone to Short- and Long-Term Thiazide Therapy of Essential Hypertension
- (2010) P. Brummelen et al. ACTA MEDICA SCANDINAVICA
- Glucose-Induced Regulation of NHEs Activity and SGLTs Expression Involves the PKA Signaling Pathway
- (2010) Olívia Beloto-Silva et al. JOURNAL OF MEMBRANE BIOLOGY
- Glucose-transporter–mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients
- (2010) Dirk von Lewinski et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started